Gennex Laboratories Limited (BOM:531739)

Market Cap	2.98B
Revenue (ttm)	1.31B
Net Income (ttm)	188.46M
Shares Out	227.45M
EPS (ttm)	0.76
PE Ratio	17.29
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	439,739
Average Volume	376,336
Open	11.91
Previous Close	12.57
Day's Range	11.15 - 12.49
52-Week Range	11.15 - 29.00
Beta	0.66
RSI	49.85
Earnings Date	May 30, 2025

About Gennex Laboratories

Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, Methocarbamol, Fexifenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl, and Allopurinol. It operates in India, Colombia, Egypt, Germany, Iran, Peru, Saudi Arabia, Spain, Thailand, and Vietnam. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, Indi...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 129
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531739

Financial Performance

In 2023, Gennex Laboratories's revenue was 867.14 million, an increase of 32.18% compared to the previous year's 656.03 million. Earnings were 131.75 million, an increase of 167.74%.